Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.88 |
| ▸ | TP53 | P04637 | 4/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.88 |
| ▸ | GMNN | O75496 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.88 |
| ▸ | THPO | P40225 | 2/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.85 |
| ▸ | NPC1 | O15118 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL28566200 | 0.99 | MEN1 (0.85) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL15346561 | 0.99 | SLC6A2 (0.87) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL5531496 | 0.94 | MEN1 (0.95) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL33371 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL4963372 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL3866334 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL23230 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL6701905 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL7327367 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL1560715 | 0.94 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112552188-B | Preparation method of sertraline hydrochloride crystal form I | 山西仟源医药集团股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-112552188-A | Process for the preparation of sertraline hydrochloride form I | 山西仟源医药集团股份有限公司 | 2021-03-26 | — | — | CN | claimed |
| EP-1463711-A4 | A NOVEL POLYMORPH OF SERTRALINE HYDROCHLORIDE AND COMPOSITION CONTAINING THEREOF, NOVEL METHODS FOR PREPARATION OF SERTRALINE HYDROCHLORIDE POLYMORPHS AND AMORPHOUS FORM | TEVA PHARMA (IL) | 2007-12-19 | — | — | EP | claimed |
| EP-1637515-A1 | Sertraline hydrochloride polymorphs | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-22 | — | — | EP | claimed |
| EP-1630156-A1 | Sertraline hydrochloride polymorphs | Teva Pharmaceutical Industries Ltd (IL) | 2006-03-01 | — | — | EP | claimed |
| US-6872853-B1 | Polymorphic forms of sertraline hydrochloride | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-03-29 | — | — | US | claimed |
| CN-1589256-A | Novel polymorphic forms of sertraline hydrochloride and compositions containing them, novel process for preparing sertraline hydrochloride polymorphic forms and amorphous forms | TEVA PHARMA CO LTD (IL) | 2005-03-02 | — | — | CN | claimed |
| EP-1463711-A1 | A NOVEL POLYMORPH OF SERTRALINE HYDROCHLORIDE AND COMPOSITION CONTAINING THEREOF, NOVEL METHODS FOR PREPARATION OF SERTRALINE HYDROCHLORIDE POLYMORPHS AND AMORPHOUS FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-06 | — | — | EP | claimed |
| EP-1133459-A4 | SERTRALINE HYDROCHLORIDE POLYMORPHS | TEVA PHARMA (US) | 2004-09-29 | — | — | EP | claimed |
| US-6600073-B1 | Sertraline hydrochloride Form III may be produced by heating sertraline hydrochloride Forms V and VI. Sertraline hydrochloride Forms V and VI may be produced from either sertraline hydrochloride or sertraline base by | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-07-29 | — | — | US | claimed |
| US-20030055112-A1 | Sertraline hydrochloride polymorphs | SCHWARTZ EDUARD (IL) | 2003-03-20 | — | — | US | claimed |
| US-6500987-B1 | PRODUCING FORMS II, III, V, VI, VII, VIII, IX AND X; HEATING, SLURRYING, CRYSTALLIZATION, SUSPENSION, FILTRATION, ACIDIFI-CATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-31 | — | — | US | claimed |
| US-6495721-B1 | MAKING SERTRALINE HYDROCHLORIDE FORM II FROM SERTRALINE BASE OR SERTRALINE MANDELATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-17 | — | — | US | claimed |
| CN-1384816-A | Polymorphic forms of sertraline hydrochloride | CIBA SC HOLDING AG (CH) | 2002-12-11 | — | — | CN | claimed |
| US-20020183555-A1 | Sertraline hydrochloride form II and methods for the preparation thereof | SCHWARTZ EDUARD (IL) | 2002-12-05 | — | — | US | claimed |
| EP-1224160-A1 | POLYMORPHIC FORMS OF SERTRALINE HYDROCHLORIDE | Ciba SC Holding AG (CH) | 2002-07-24 | — | — | EP | claimed |
| EP-1133459-A1 | SERTRALINE HYDROCHLORIDE FORM V | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032551-A9 | SERTRALINE HYDROCHLORIDE POLYMORPHS | TEVA PHARMA (IL) | 2001-07-19 | — | — | WO | claimed |
| WO-2001032601-A1 | POLYMORPHIC FORMS OF SERTRALINE HYDROCHLORIDE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-05-10 | — | — | WO | claimed |
| WO-2000032551-A1 | SERTRALINE HYDROCHLORIDE POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183555-A1 | Sertraline hydrochloride form II and methods for the preparation thereof | HTR5A, SLC6A4, HTR2C | SLC6A4 2/4885MEN1 2229/4885KMT2A 2023/4885 |
| US-20030055112-A1 | Sertraline hydrochloride polymorphs | HTR5A, SLC6A4, HTR2C | SLC6A4 2/4885MEN1 4675/4885KMT2A 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.